Session » Vasculitis Poster III: Other Vasculitis Syndromes

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2734

A Comparison of Current Practice to New Vasculitis Treatment Guidelines

9:00AM-11:00AM: Abstract Number: 2742

A Retrospective Study Comparing the Phenotype and Outcomes of Patients with Polyarteritis Nodosa between UK and Turkish Cohorts

9:00AM-11:00AM: Abstract Number: 2750

A Serum Metabolomic Analysis in Behcet’s Disease: A Preliminary Study

9:00AM-11:00AM: Abstract Number: 2723

Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group

9:00AM-11:00AM: Abstract Number: 2721

Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study

9:00AM-11:00AM: Abstract Number: 2724

Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases

9:00AM-11:00AM: Abstract Number: 2727

Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study

9:00AM-11:00AM: Abstract Number: 2720

Behcet’s Disease in Southeastern Michigan: A Single Center Comparative Study

9:00AM-11:00AM: Abstract Number: 2719

Can Annexin A1 Expression on Neutrophils Distinguish Adult IgA Vasculitis from Other Small Vessel Vasculitides?

9:00AM-11:00AM: Abstract Number: 2733

Clinical Characteristics and Treatment Outcomes of Patients with Behçet’s Disease and Vascular Involvement

9:00AM-11:00AM: Abstract Number: 2730

Clinical Features and Treatment of Central Nervous System Vasculitis Associated with Acute Posterior Multifocal Placoid Pigment Epitheliopathy

9:00AM-11:00AM: Abstract Number: 2746

Comparison between IgG and IgM Type Anti-Alpha-Enolase Antibody in Patients with Behcet’s Disease According to the Disease Severity

9:00AM-11:00AM: Abstract Number: 2740

Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases

9:00AM-11:00AM: Abstract Number: 2726

Differentiating Features of Primary Angiitis of Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome: Clinical and Radiological Evaluation

9:00AM-11:00AM: Abstract Number: 2749

Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries

9:00AM-11:00AM: Abstract Number: 2716

Gastrointestinal Involvement in Adult IgA Vasculitis (Henoch–Schönlein purpura): Initial Manifestations and Outcomes

9:00AM-11:00AM: Abstract Number: 2748

Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study

9:00AM-11:00AM: Abstract Number: 2738

Infectious Complications in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2718

Is Smoking Important in Adult IgA Vasculitis?

9:00AM-11:00AM: Abstract Number: 2735

Is There an Association between Adult IgA Vasculitis and Cancer?

9:00AM-11:00AM: Abstract Number: 2717

Late Onset of IgA Vasculitis Is Associated with More Severe Renal Involvement

9:00AM-11:00AM: Abstract Number: 2722

Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases

9:00AM-11:00AM: Abstract Number: 2747

Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide

9:00AM-11:00AM: Abstract Number: 2744

Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment

9:00AM-11:00AM: Abstract Number: 2736

Long-Term Survival in Systemic Necrotizing Vasculitides

9:00AM-11:00AM: Abstract Number: 2739

Onco-Hematological Malignancies in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2745

Prevalence of Vasculitides As Extraintestinal Manifestation of Inflammatory Bowel Disease (IBD)

9:00AM-11:00AM: Abstract Number: 2737

Pulmonary Manifestations of Primary Systemic Vasculitides

9:00AM-11:00AM: Abstract Number: 2732

Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 2743

Requirement and Response Rates of Biologic Agents in Polyarteritis Nodosa (PAN)

9:00AM-11:00AM: Abstract Number: 2741

Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons

9:00AM-11:00AM: Abstract Number: 2752

Risk of Hospitalizations for Venous Thromboembolism Among Patients with Selected Systemic Vasculitides: A Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 2728

Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients

9:00AM-11:00AM: Abstract Number: 2729

Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome

9:00AM-11:00AM: Abstract Number: 2731

The Utility of Unbiased Metagenomic Next Generation Sequencing in the Management of Patients with CNS Vasculitis

9:00AM-11:00AM: Abstract Number: 2751

Tocilizumab in the Treatment of Severe and/or Refractory Behcet’s Disease：a Single-Centre Experience in China

9:00AM-11:00AM: Abstract Number: 2725

Understanding Vasculitis Patients’ Ability to Work with Numbers

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].